NCT04623541 ACTIVE NOT RECRUITING Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Genmab
NCT07061951 RECRUITING Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
NCT04416984 ACTIVE NOT RECRUITING Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Allogene Therapeutics
NCT05479994 ACTIVE NOT RECRUITING Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeiGene
NCT05873712 RECRUITING Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Aseel Alsouqi
NCT06588478 RECRUITING A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
NCT06364423 RECRUITING Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT05702853 RECRUITING Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
NCT04195633 RECRUITING Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT05458297 RECRUITING A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Merck Sharp & Dohme LLC
NCT06524375 ACTIVE NOT RECRUITING A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Genentech, Inc.
NCT04624633 ACTIVE NOT RECRUITING Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Jennifer R. Brown, MD, PhD
NCT02629809 ACTIVE NOT RECRUITING Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT03986034 RECRUITING Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
National Heart, Lung, and Blood Institute (NHLBI)
NCT05589896 RECRUITING A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT04169737 RECRUITING Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT04186520 RECRUITING CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT06637501 ACTIVE NOT RECRUITING A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
NCT05006716 RECRUITING A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT02756897 ACTIVE NOT RECRUITING Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT05336812 RECRUITING Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT06466122 RECRUITING Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Kerry Rogers
NCT02846623 ACTIVE NOT RECRUITING Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
NCT05183854 RECRUITING Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
University of Utah
NCT07221500 RECRUITING A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
NCT03580928 ACTIVE NOT RECRUITING Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Dana-Farber Cancer Institute
NCT07271667 RECRUITING A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
NCT06533579 RECRUITING Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
NCT05677919 ACTIVE NOT RECRUITING Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
NCT06644183 RECRUITING Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
NCT04895436 RECRUITING Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT03516617 RECRUITING Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT03513562 ACTIVE NOT RECRUITING Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Ohio State University Comprehensive Cancer Center
NCT06001385 ACTIVE NOT RECRUITING HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT04560322 RECRUITING Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
NCT04419519 ACTIVE NOT RECRUITING Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Memorial Sloan Kettering Cancer Center
NCT03932331 ACTIVE NOT RECRUITING Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
NCT02427451 ACTIVE NOT RECRUITING Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Kerry Rogers
NCT07024706 NOT YET RECRUITING Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
AstraZeneca
NCT06333262 RECRUITING Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Inhye Ahn
NCT04458610 ACTIVE NOT RECRUITING Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT07194980 NOT YET RECRUITING Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
NCT03960840 ACTIVE NOT RECRUITING Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT02717611 ACTIVE NOT RECRUITING A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Acerta Pharma BV
NCT06043674 RECRUITING Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Christine Ryan
NCT05417165 RECRUITING Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Seema Bhat
NCT02518555 ACTIVE NOT RECRUITING Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach
NCT04523428 RECRUITING REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT07108998 RECRUITING Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Zulfa Omer
NCT07014917 RECRUITING Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Zulfa Omer
NCT03277729 ACTIVE NOT RECRUITING A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
NCT03961672 ACTIVE NOT RECRUITING Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
NCT04505254 RECRUITING Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT07154264 RECRUITING A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
NCT02966756 RECRUITING A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
NCT03467867 ACTIVE NOT RECRUITING A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
NCT06863402 RECRUITING Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
NCT03622788 ACTIVE NOT RECRUITING Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT06697184 ACTIVE NOT RECRUITING A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
BeiGene
NCT06757647 RECRUITING Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Seema Bhat
NCT07052695 RECRUITING Mosunetuzumab for CLL MRD Clearance
Inhye Ahn
NCT05672173 RECRUITING Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
City of Hope Medical Center
NCT07218510 RECRUITING Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
NCT05168930 RECRUITING Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Dana-Farber Cancer Institute
NCT04844528 RECRUITING Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
University of Utah
NCT04963946 ACTIVE NOT RECRUITING STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
French Innovative Leukemia Organisation
NCT07259070 NOT YET RECRUITING Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06539182 RECRUITING DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Dizal Pharmaceuticals
NCT03734198 ACTIVE NOT RECRUITING Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
French Innovative Leukemia Organisation
NCT06958705 RECRUITING Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
NCT03128879 RECRUITING Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
NCT06839053 RECRUITING Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
NCT04941716 RECRUITING Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
NCT04060277 ACTIVE NOT RECRUITING Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT05643742 RECRUITING A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics AG
NCT06967610 RECRUITING Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
M.D. Anderson Cancer Center
NCT05718869 ACTIVE NOT RECRUITING Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
NCT04205409 ACTIVE NOT RECRUITING Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
NCT05031897 RECRUITING Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT06520098 RECRUITING A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development
NCT05388006 RECRUITING Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT04447768 ACTIVE NOT RECRUITING The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Memorial Sloan Kettering Cancer Center
NCT04679012 RECRUITING Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Weill Medical College of Cornell University
NCT05672251 RECRUITING Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT06979076 NOT YET RECRUITING A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc
NCT05944978 ACTIVE NOT RECRUITING A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06849713 RECRUITING Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Massachusetts General Hospital
NCT03824483 RECRUITING Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
NCT06859424 RECRUITING A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT03162536 ACTIVE NOT RECRUITING A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT04501939 ACTIVE NOT RECRUITING Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
University of California, San Diego
NCT04722172 ACTIVE NOT RECRUITING A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
NCT02506933 ACTIVE NOT RECRUITING Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT03765177 RECRUITING CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Ottawa Hospital Research Institute
NCT06978088 RECRUITING LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Zulfa Omer
NCT03534323 ACTIVE NOT RECRUITING Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
NCT06812715 RECRUITING Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Peter MacCallum Cancer Centre, Australia
NCT04904588 ACTIVE NOT RECRUITING HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT05805605 RECRUITING Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT03314974 RECRUITING Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT06862323 NOT YET RECRUITING Time Restricted Eating in Haematological Malignancies
British Columbia Cancer Agency
NCT07003464 NOT YET RECRUITING Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University
NCT05908409 RECRUITING A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
IDP Discovery Pharma S.L.
NCT04657094 ACTIVE NOT RECRUITING Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
NCT05294731 RECRUITING Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeiGene
NCT04494503 RECRUITING Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
NCT02952508 ACTIVE NOT RECRUITING Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Cellectar Biosciences, Inc.
NCT06059391 RECRUITING CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT05672355 RECRUITING A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
NCT05281809 RECRUITING Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT02339922 ACTIVE NOT RECRUITING Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT06762431 ENROLLING BY INVITATION Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Vitebsk Regional Clinical Cancer Centre
NCT03153202 ACTIVE NOT RECRUITING Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Joshua Brody
NCT06544785 RECRUITING Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation
NCT06506643 RECRUITING Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
NCT02514083 ACTIVE NOT RECRUITING A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Heart, Lung, and Blood Institute (NHLBI)
NCT03676504 RECRUITING Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
NCT06476899 NOT YET RECRUITING A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
Fei Li
NCT04082897 ACTIVE NOT RECRUITING ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation
Niguarda Hospital
NCT05869279 RECRUITING Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
NCT06367374 NOT YET RECRUITING MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China
NCT05791409 RECRUITING Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT05694312 RECRUITING Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT05478512 RECRUITING Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT05959694 RECRUITING A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04758975 RECRUITING Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Paolo Ghia
NCT04908228 RECRUITING Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
Paolo Ghia
NCT05918276 NOT YET RECRUITING Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
Nanfang Hospital, Southern Medical University
NCT04935684 RECRUITING Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT03226301 ACTIVE NOT RECRUITING A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT04639362 ACTIVE NOT RECRUITING CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT04771507 RECRUITING A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Jeanette Lundin
NCT03980002 RECRUITING A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Institute of Hematology & Blood Diseases Hospital, China
NCT03514017 TERMINATED Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT03609593 COMPLETED Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Nicole Lamanna
NCT04282018 COMPLETED Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeiGene
NCT02649387 COMPLETED Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Mayo Clinic
NCT04809467 TERMINATED A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Incyte Corporation
NCT03204188 COMPLETED Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT04116437 COMPLETED Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeiGene
NCT03740529 COMPLETED A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Loxo Oncology, Inc.
NCT02337829 COMPLETED Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
NCT04163718 TERMINATED TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
H. Lee Moffitt Cancer Center and Research Institute
NCT03708003 TERMINATED Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
NCT04230304 TERMINATED Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Mayo Clinic
NCT05317936 TERMINATED Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
M.D. Anderson Cancer Center
NCT04191187 COMPLETED Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT02362035 COMPLETED ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acerta Pharma BV
NCT04010968 COMPLETED Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia
French Innovative Leukemia Organisation
NCT05105841 COMPLETED Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
NCT02315768 COMPLETED Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
NCT03207555 COMPLETED Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT02793544 COMPLETED HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT02722668 COMPLETED UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT03333486 TERMINATED Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT06839872 WITHDRAWN A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca
NCT03246906 TERMINATED Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT05405309 TERMINATED RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
University of Utah
NCT04189952 TERMINATED Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
NCT04685915 WITHDRAWN Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Inhye Ahn
NCT03492125 TERMINATED A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
NCT03615105 TERMINATED Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
NCT04419389 TERMINATED APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Aprea Therapeutics
NCT02396134 COMPLETED Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT04312841 COMPLETED Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT03088878 COMPLETED A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Oncternal Therapeutics, Inc
NCT04716075 COMPLETED Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Polish Lymphoma Research Group
NCT04305444 TERMINATED Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
NCT03997968 COMPLETED A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT02910583 COMPLETED Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Pharmacyclics LLC.
NCT05269940 COMPLETED A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
Nanjing Zenshine Pharmaceuticals
NCT03206918 COMPLETED Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
NCT04358458 TERMINATED First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
NCT03788291 COMPLETED Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
NCT05720052 TERMINATED A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
NCT03088709 TERMINATED Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT02742090 TERMINATED Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
TG Therapeutics, Inc.
NCT05465876 WITHDRAWN Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Sunnybrook Health Sciences Centre
NCT03056339 COMPLETED Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT02420912 COMPLETED Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
M.D. Anderson Cancer Center
NCT06247540 WITHDRAWN Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Northwestern University
NCT03128359 COMPLETED High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT02332980 COMPLETED Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
NCT05028374 COMPLETED COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NCT03734601 COMPLETED Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT04808570 TERMINATED A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03572634 TERMINATED Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Sumitomo Pharma America, Inc.
NCT02869633 COMPLETED Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
NCT03096782 COMPLETED Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT02661035 COMPLETED Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT02340780 COMPLETED Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
NCT04029038 WITHDRAWN Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT03010358 COMPLETED Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Alexey Danilov, MD
NCT03702231 COMPLETED Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
National Heart, Lung, and Blood Institute (NHLBI)
NCT04016805 TERMINATED Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
NCT02656303 TERMINATED A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
TG Therapeutics, Inc.
NCT04149821 TERMINATED Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
NCT02440685 TERMINATED A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
NCT02581007 COMPLETED Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT05365100 WITHDRAWN A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
BioNova Pharmaceuticals (Shanghai) LTD.
NCT05209308 WITHDRAWN Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
MEI Pharma, Inc.
NCT03370185 WITHDRAWN Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
SecuraBio
NCT04030195 COMPLETED Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
NCT02593123 COMPLETED Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT02556931 COMPLETED Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04504708 TERMINATED Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Hangzhou Zenshine Pharmaceuticals Co., Ltd.
NCT02225275 TERMINATED Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT04282174 WITHDRAWN CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Baptist Health South Florida
NCT03379051 TERMINATED Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
NCT04665115 WITHDRAWN Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
NCT03207256 TERMINATED Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
TG Therapeutics, Inc.
NCT04155840 TERMINATED Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
NCT04660045 WITHDRAWN Early Intervention With Acalabrutinib in Patients With High Risk CLL
Weill Medical College of Cornell University
NCT04209621 TERMINATED Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT03939234 COMPLETED Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
Lars Møller Pedersen
NCT02968563 COMPLETED Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
NCT03153514 TERMINATED Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
German CLL Study Group
NCT02983617 COMPLETED Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
NCT02639910 COMPLETED Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
MorphoSys AG
NCT03943342 WITHDRAWN Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Kerry Rogers
NCT03045328 COMPLETED Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Steven E. Coutre
NCT02424968 COMPLETED CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT03041636 COMPLETED Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT03076437 COMPLETED Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
NCT03755947 COMPLETED Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de Hemopatías Malignas
NCT02309515 TERMINATED Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Mayo Clinic
NCT03037645 TERMINATED Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Sunesis Pharmaceuticals
NCT02991898 TERMINATED Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03097770 COMPLETED Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT01003769 TERMINATED Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Mayo Clinic
NCT02689141 COMPLETED Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
NCT02481297 COMPLETED Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
NCT02320487 COMPLETED A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
NCT02557516 TERMINATED Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
Innate Pharma
NCT02530515 COMPLETED Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT03195010 TERMINATED Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT03438344 WITHDRAWN Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02877082 TERMINATED Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
NCT02371590 WITHDRAWN Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
NCT02662296 WITHDRAWN Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT02677948 WITHDRAWN Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of Michigan Rogel Cancer Center
NCT02371577 WITHDRAWN Evaluation of the Immune Restoration Potential Of Lenalidomide
University of California, San Diego
NCT02285244 WITHDRAWN Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
James Blachly